Peptide RX

back to claim graph

proof receipt / target

GRIN2B

NMDA receptor subunit NR2B

grade B status cognitive receipt 82a92f61048b proof 33%

what this node claims

GRIN2B

NMDA receptor subunit NR2B

evidence / risk instrument

44%
thin proof
structure evidence gates risk export lineage 44
low debt pressure 24%
28%structuredebt
pLDDT pending
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine

proof completeness

33% missing alphafold_metric, candidate, finding, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

binding partners
    context annotations
    0
    family
    ligand_gated_ion_channel
    functional sites
      gene symbol
      GRIN2B
      go terms
        uniprot
        Q13224

        AlphaFold metrics visual

        Low-confidence regions present

        60.7

        1484 residues / min 24.03 / max 96.0 / source alphafold db

        PAE matrix for linked target
        Very high 17.8% 264 residues / >=90
        Confident 29.2% 434 residues / 70-89
        Low 8.8% 131 residues / 50-69
        Very low 44.1% 655 residues / <50

        weak structural context; downstream claims should be conservative

        Near-complete coverage / observed 1484 of 1484 residues.

        • residues 845-1484 / mean 33.4
        • residues 1-32 / mean 42.87
        • residues 581-600 / mean 52.73
        • residues 44-58 / mean 60.07
        proof debt register

        Visible limits, not hidden cleanup.

        24%

        Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

        medium missing functional-site annotations link target annotation, GO term, or binding-site context
        low computational-only status add independent evidence, challenge result, or witness review before strengthening
        low low-confidence AlphaFold regions likely attach pLDDT series, PAE matrix, or coverage evidence
        medium no candidate yet leave visible until a stronger public receipt resolves it

        weakness and challenge edges

        What would stop this from becoming stronger.

        debt severity export claim strength next proof needed
        missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context
        computational-only status low visible watch add independent evidence, challenge result, or witness review before strengthening
        low-confidence AlphaFold regions likely low visible watch attach pLDDT series, PAE matrix, or coverage evidence
        no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it

        what supports it

        No upstream proof edge yet.

        what it supports

        target has structure prediction target:1b5f0efe-ab68-4bed-9fe3-3dbae6604183 -> fold:dc16af81-4f81-4efe-9fab-d9d95327c37b folds_to / B / 0.607

        Research-use boundary

        This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.